Patent intelligence · US
US 2017056477
Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier
Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier
Patent details — US 2017056477
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 2, 2017
- Expiration
- Feb 25, 2037
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 08 A I, A61K 9/ 19 A I, A61K 38/ 27 A I
Quick answer
US 2017056477 (Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier) is held by ASCENDIS PHARMA GROWTH DISORDERS DIV AS [DK]. Status: granted. Granted Mar 2, 2017. Expires Feb 25, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 08 A I, A61K 9/ 19 A I, A61K 38/ 27 A I, A61K 45/ 06 A I, A61K 47/ 10 A I
More from ASCENDIS PHARMA GROWTH DISORDERS DIV AS [DK]
Related pharmaceutical patents in our USPTO index.
-
US 2025295738
Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily Somatropin
granted -
CA 3131817
FORMES POSOLOGIQUES D'HORMONE DE CROISSANCE A ACTION PROLONGEE AYANT UNE EFFICACITE SUPERIEURE A UNE DOSE DE SOMATROPINE QUOTIDIENNE
granted -
US 2017354716
Novel Polymeric hGH Prodrugs
granted -
US 2017312342
Long-Acting Growth Hormone Dosage Forms
granted -
US 2016206702
PEGylated Recombinant Human Growth Hormone Compounds
granted
Frequently asked questions
What is US patent 2017056477?
US 2017056477 (Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier) is held by ASCENDIS PHARMA GROWTH DISORDERS DIV AS [DK]. Status: granted. Granted Mar 2, 2017. Expires Feb 25, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2017056477?
ASCENDIS PHARMA GROWTH DISORDERS DIV AS [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 2017056477 expire?
Our index shows an expiration date of Feb 25, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.